Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed squamous cell cancer of the head and neck~  * Recurrent or metastatic disease~ * Determined to be incurable by surgery or radiotherapy~* Measurable disease~* No tumor involvement encasing or too close in proximity to a major artery or vein~* No known brain metastases~* No prior or concurrent CNS disease~* No primary brain tumor~* Performance status - ECOG 0-2~* Performance status - Karnofsky 60-100%~* More than 12 weeks~* No history of bleeding diathesis~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* INR less than 1.5~* Bilirubin normal~* AST and ALT no greater than 2.5 times upper limit of normal~* Creatinine normal~* Creatinine clearance at least 60 mL/min~* No significant renal impairment~* 24-hour urinary protein less than 0.5 g required if more than trace proteinuria at baseline~* No uncontrolled hypertension~* No symptomatic congestive heart failure~* No serious cardiac arrhythmia requiring medication~* No deep venous thrombosis~* No prior stroke~* No New York Heart Association class II-IV heart disease~* No grade II-IV peripheral vascular disease within the past year~* No arterial thromboembolic event within the past 6 months, including any of the following:~  * Unstable angina pectoris~ * Myocardial infarction~ * Transient ischemic attack~ * Cerebrovascular accident~* No clinically significant peripheral artery disease~* No significant ophthalmologic abnormalities\* including any of the following:~  * Severe dry eye syndrome~ * Keratoconjunctivitis sicca~ * Sjögren's syndrome~ * Severe exposure keratopathy~ * Disorders that might increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, neutrophilic keratitis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prior allergic reactions to compounds of similar chemical or biologic composition to bevacizumab or other study agents~* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies~* No significant traumatic injury within the past 28 days~* No other concurrent uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~* No ongoing or active infection requiring parenteral antibiotics~* No serious non-healing wound ulcer or bone fracture~* No seizures not controlled by standard medical therapy~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)~* More than 4 weeks since prior radiotherapy~* More than 4 weeks since prior major surgery~* More than 4 weeks since prior open biopsy~* Recovered from prior therapy~* No more than 1 prior regimen for recurrent disease~* No prior epidermal growth factor receptor (EGFR)-based therapy for recurrent disease~* No prior vascular EGFR-based therapy for recurrent disease~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent chronic use of aspirin (325 mg/day or more) or other nonsteroidal anti-inflammatory drugs~* No concurrent warfarin or heparin, including low-molecular weight heparin~* No other concurrent or recent (within 1 month) thrombolytic agents or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).